These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26378211)

  • 41. Trials of novel oral anticoagulants for stroke prevention in patients with non-valvular atrial fibrillation.
    Halperin JL; Dorian P
    Curr Cardiol Rev; 2014 Nov; 10(4):297-302. PubMed ID: 24821657
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Anticoagulants for stroke prevention in nonvalvular atrial fibrillation: new agents and an updated understanding.
    Ganjehei L; Wilson JM
    Tex Heart Inst J; 2012; 39(4):517-25. PubMed ID: 22949768
    [No Abstract]   [Full Text] [Related]  

  • 43. Recurrent Hospitalization Among Patients With Atrial Fibrillation Undergoing Intracoronary Stenting Treated With 2 Treatment Strategies of Rivaroxaban or a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy.
    Gibson CM; Pinto DS; Chi G; Arbetter D; Yee M; Mehran R; Bode C; Halperin J; Verheugt FW; Wildgoose P; Burton P; van Eickels M; Korjian S; Daaboul Y; Jain P; Lip GY; Cohen M; Peterson ED; Fox KA
    Circulation; 2017 Jan; 135(4):323-333. PubMed ID: 27881555
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Clinical Application and Pharmacodynamic Monitoring of Apixaban in a Patient with End-Stage Renal Disease Requiring Chronic Hemodialysis.
    Kufel WD; Zayac AS; Lehmann DF; Miller CD
    Pharmacotherapy; 2016 Nov; 36(11):e166-e171. PubMed ID: 27643979
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Direct oral factor Xa inhibitors for the prevention of non-central nervous systemic embolism patients with non-valvular atrial fibrillation - a systematic review and meta-analysis.
    Gandara V; Vazquez F; Gandara E
    Vasa; 2016; 45(4):293-8. PubMed ID: 27428497
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Edoxaban (Lixiana°).
    Prescrire Int; 2017 Jan; 26(178):13-14. PubMed ID: 30730636
    [No Abstract]   [Full Text] [Related]  

  • 47. Response by Piccini et al to Letters Regarding Article, "Polypharmacy and the Efficacy and Safety of Rivaroxaban Versus Warfarin in the Prevention of Stroke in Patients With Nonvalvular Atrial Fibrillation".
    Piccini JP; Hellkamp AS; Washam JB; Becker RC; Breithardt G; Berkowitz SD; Halperin JL; Hankey GJ; Hacke W; Mahaffey KW; Nessel CC; Singer DE; Fox KA; Patel MR
    Circulation; 2016 Jul; 134(2):e7-8. PubMed ID: 27400902
    [No Abstract]   [Full Text] [Related]  

  • 48. Model-based meta-analysis to evaluate optimal doses of direct oral factor Xa inhibitors in atrial fibrillation patients.
    Yoshioka H; Sato H; Hatakeyama H; Hisaka A
    Blood Adv; 2018 May; 2(10):1066-1075. PubMed ID: 29760204
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Unresolved issues in the use of direct acting oral anticoagulants.
    Chan N; Hirsh J
    Expert Rev Cardiovasc Ther; 2023; 21(12):913-921. PubMed ID: 37837206
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Use of Guidelines for Reducing Stroke Risk in Patients With Nonvalvular Atrial Fibrillation: A Review From a Latin American Perspective.
    Cantú-Brito C; Silva GS; Ameriso SF
    Clin Appl Thromb Hemost; 2018 Jan; 24(1):22-32. PubMed ID: 28992764
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Clinical profile, management and outcomes in a cohort of elderly and highly comorbid patients with nonvalvular atrial fibrillation treated with rivaroxaban in routine practice.
    Brun Guinda D; Callen García Ó; Ondiviela Pérez J; Gracia Aznarez M; Artero Bello P; Rivero Fernandez E; Marquina Barcos A; Villarroel Salcedo M
    Future Cardiol; 2018 May; 14(3s):39-45. PubMed ID: 29848090
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Does proton pump inhibition change the on-treatment anti-Xa activity in xabans-treated patients with atrial fibrillation? A pilot study.
    Bolek T; Samoš M; Škorňová I; Stančiaková L; Staško J; Korpallová B; Galajda P; Kubisz P; Mokáň M
    J Thromb Thrombolysis; 2019 Jan; 47(1):140-145. PubMed ID: 30288664
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Effectiveness and safety of rivaroxaban in a cohort of 142 patients with nonvalvular atrial fibrillation treated with rivaroxaban for the prevention of stroke.
    Cerezo-Manchado JJ; Navarro-Almenzar B; Elvira-Ruiz G; García-Candel F; Flores-Blanco PJ; Caro-Martínez C; Manzano-Fernández S; García-Iniesta N; Sánchez-García J; Cabañas-Perianes V; Moraleda-Jiménez JM
    Future Cardiol; 2018 May; 14(3s):31-37. PubMed ID: 29848091
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Reversal strategies for non-vitamin K antagonist oral anticoagulants].
    Larsen FU; Hvas AM; Grove EL
    Ugeskr Laeger; 2016 Oct; 178(40):. PubMed ID: 27697119
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Review of Direct Oral Anticoagulants and Guide for Effective Drug Utilization.
    Khachatryan T; Hauschild C; Hoff J; Contractor T; Khachatryan A; Tran H; Matsuo B; Jacobson A; Hilliard A
    Am J Cardiovasc Drugs; 2019 Dec; 19(6):525-539. PubMed ID: 30941708
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Anticoagulation with rivaroxaban in a hematology unit: clinical profile, events and discontinuation rates in real-life patients with nonvalvular atrial fibrillation.
    Gavín Sebastián O; Izuzquiza Fernández M; Martínez Fernández R; Palomera Bernal L
    Future Cardiol; 2018 May; 14(3s):25-30. PubMed ID: 29848092
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Comparative risk impact of edoxaban in the management of stroke and venous thromboembolism.
    Tellor KB; Van Tuyl JS; Armbruster AL
    Ther Clin Risk Manag; 2016; 12():667-74. PubMed ID: 27217759
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Platelet Aggregation in Direct Oral Factor Xa Inhibitors-treated Patients With Atrial Fibrillation: A Pilot Study.
    Bánovčin P; Škorňová I; Samoš M; Schnierer M; Bolek T; Kovář F; Staško J; Kubisz P; Mokáň M
    J Cardiovasc Pharmacol; 2017 Oct; 70(4):263-266. PubMed ID: 28708713
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Clinical Safety Outcomes in Patients With Nonvalvular Atrial Fibrillation on Rivaroxaban and Diltiazem.
    Bartlett JW; Renner E; Mouland E; Barnes GD; Kuo L; Ha NB
    Ann Pharmacother; 2019 Jan; 53(1):21-27. PubMed ID: 30099888
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The Use of Edoxaban in Patients with Nonvalvular Atrial Fibrillation and Venous Thromboembolism: A Pharmacist's Perspective.
    Stacy ZA; Richter SK
    Hosp Pharm; 2016 Jan; 51(1):26-34. PubMed ID: 38745713
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.